Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes.

Allergic Rhinitis Clinical Trial

— NMR  

Official title:

Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes Using the Environmental Exposure Unit (EEU). Part 2.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02230475
• Other study ID #: Kingston General Hospital
• Status: Completed
• Phase: N/A
• First received: August 15, 2014
• Last updated: April 20, 2015
• Start date: August 2014
• Est. completion date: September 2014

Study information

• Verified date: April 2015
• Source: Queen's University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

This clinical study will use the Environmental Exposure Unit (EEU) to generate allergic rhinitis symptoms in participants under controlled conditions, to collect well-characterized biological samples (urine and blood) before and after they develop these symptoms. The EEU provides the ability to control the timing, duration and levels of allergen exposure, and also other outside environmental factors, yielding ideal biologic samples for analysis with novel, cutting-edge molecular techniques. Results from the analysis of these unique allergic rhinitis samples should help determine if the technique of urine Nuclear Magnetic Resonance analysis could be a useful diagnostic tool in allergic rhinitis. IgE testing will be done on blood samples and compared to spin prick testing and symptoms of allergic rhinitis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Participant is a healthy, ambulatory male or female volunteer 18 to 55 years of age.

• Participant has a history of Seasonal Allergic Rhinitis due to ragweed for the last two consecutive ragweed seasons.

• Participant has a positive response (wheal diameter greater than or equal to 3 mm larger than diluent control) to a skin prick test to short ragweed allergen at screening or within 12 months of screening visit.

Exclusion Criteria:

• Participant is a female that is pregnant, lactating or actively trying to become pregnant.

• smokers

• Participant is unable to comply with the washout periods for prohibited medications.

• Participant is currently receiving allergen specific immunotherapy injections.

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis

Locations

Country	Name	City	State
Canada	Kingston General Hospital	Kingston	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metabolomics	Determine if urine NMR metabolic profiles from participants with allergic rhinitis will be significantly different from that of healthy participants (healthy controls were included in part 1 of the 2010 study) and if changes in urine NMR profile correlate with disease severity. NMR will be reported	Participant visits from July 2014 - September 2014; samples and data will be analyzed and presented for up to 2 years following participant visits.	No
Secondary	IgE testing	Blood samples will be collected from participants to measure ragweed specific IgE levels and compare them to their individual skin testing wheal size as well as their symptoms of allergic rhinitis in the EEU before and after pollen exposure. These symptoms are reported on a questionnaire completed by the participant every 20 minutes.	Participant visits from July 2014 - September 2014; samples and data will be analyzed and presented for up to 2 years following participant visits.	No
Secondary	Epigenetics	Blood samples will be collected to examine epigenetic biomarkers in relation to symptoms of allergic rhinitis before and after exposure in the EEU. These symptoms are reported on a questionnaire completed by the participant every 20 minutes.	Participant visits from July 2014 - September 2014; samples and data will be analyzed and presented for up to 2 years following participant visits.	No

External Links

•   Link